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Abstract 
Hydrolases containing two metal ions connected by a bridging ligand catalyze reactions important in 
carcinogensis, tissue repair, post-translational modification, control and regulation of biochemical pathways, 
and protein degradation. The aminopeptidase from Aeromonas proteolytica serves as a paradigm for the study 
of such bridged bimetallic proteases since its three-dimensional structure is known to very high resolution and 
its catalytic reaction is amenable to spectroscopic examination. Herein, we report the X-ray crystal structure at 
1.9 Å resolution of AAP complexed with 1-butaneboronic acid (BuBA). This structure suggests that this complex 
represents a snapshot of the proteolytic reaction in an arrested form between the Michaelis complex and the 
transition state. Comparison of the structure with spectroscopic and other data allows us to conclude that the 
apparently structurally symmetrical dizinc site is actually asymmetric electrostatically. 
This work was supported by the National Science Foundation (CHE-9816487 to RCH), by the National Institutes 
of Health (GM26788 to GAP and DR), and, in part, by the Macromolecular Structure and Mechanisms Training 
Grant from the NIH (CCD). 
 
Hydrolases that contain two metal ions connected by a bridging ligand catalyze such diverse reactions as the 
degradation of DNA, RNA, phospholipids, and polypeptides (1−4). They are, therefore, key players in 
carcinogenesis, tissue repair, protein maturation, hormone-level regulation, cell-cycle control, and protein 
degradation processes. In addition, binuclear metallohydrolases are involved in the degradation of agricultural 
neurotoxins, urea, antibiotics, and several phosphorus(V) materials used in chemical weaponry (5−7). These 
enzymes use different metal ion Lewis acidities in discrete binuclear sites to (1) bind and position substrate, (2) 
bind and activate a water molecule to yield an active site hydroxide nucleophile, and/or (3) stabilize the 
transition state of the hydrolytic reaction. Despite their ubiquity and the considerable structural information 
available, little is known about how bridged bimetallic centers function during catalytic turnover. 
The binuclear metallo-aminopeptidases catalyze the hydrolysis of N-terminal amino acid residues from proteins 
and polypeptides and are typically grouped into two distinct subclasses:  those that are capable of removing 
nearly any amino acid from the N-terminus of a polypeptide chain and those that selectively remove methionine 
(8−10). All of these enzymes are widely distributed in bacteria, yeast, plant, and animal tissues (10). Abnormal 
aminopeptidase activity has been associated with many health conditions and pathologies, including aging, 
cataracts, inflammation, cystic fibrosis, cancer, and leukemia; thus, their biological and medicinal significance is 
immense (8−10). For example, the naturally occurring peptide-analogue inhibitor, bestatin, was recently shown 
to significantly decrease HIV infection in males by inhibiting leucine aminopeptidase activity (11). Moreover, a 
recent study has shown that several naturally occurring aminopeptidase inhibitors (i.e., bestatin, leuhistin, and 
actinonin) inhibit matrix degradation and invasion of extracellular matrixes by fibrosarcoma cells (12). Thus, the 
inhibition of aminopeptidase activity at malignant tumors is critically important in preventing the growth and 
proliferation of cancer. This fact is underscored by the recent observation that the eukaryotic binuclear 
metallohydrolase methionine aminopeptidase II is the target for the antitumor drugs ovalicin and fumagillin (13, 
14). 
The dizinc aminopeptidase from Aeromonas proteolytica (AAP) is a small, monomeric enzyme (32 000 Da), 
thermostable for several hours at 70 °C, that has been previously crystallographically characterized (15, 16). AAP 
possesses a (μ-aqua)(μ-carboxylato)dizinc(II) core with a terminal carboxylate and histidine residue at each 
metal (Figure 1). Both Zn(II) ions in AAP have a distorted tetrahedral coordination geometry with a Zn−Zn 
distance of 3.5 Å. The X-ray crystal structure of AAP complexed to the transition state analogue inhibitor d-
iodophenylalanine hydroxamate shows that a single oxygen atom of the hydroxamate inhibitor bridges between 
the two active-site Zn(II) ions with the concomitant loss of the bridging water molecule (16). This structure is 
similar to the transition state analogue inhibited structures of bovine lens aminopeptidase (blLAP) complexed 
with l-leucinal and l-leucine phosphonic acid (LPA) (17, 18) and AAP bound by LPA (19). These structures of 
transition state analogue complexes have been interpreted as representing one stage of the reaction 
mechanism. 
 
Figure 1 Stereoimage of the native AAP active site calculated from coordinates 1AMP, (15). The zinc ions of the 
binuclear center have symmetric coordination spheres in that each has a terminal carboxylate and histidine 
residue in addition to the bridging aspartate and water molecule. Glu151, also shown, is not a metal ligand but is 
thought to participate in the hydrolytic reaction. 
 
Herein, we present the X-ray crystal structure, at 1.9 Å resolution, of AAP coordinated by the competitive 
inhibitor 1-butaneboronic acid (BuBA). Comparison of this structure with spectroscopic and X-ray 
crystallographic data from the binding of both substrate and transition state analogues of peptide hydrolysis 
reveals that the BuBA complex represents a snapshot of the proteolytic reaction in an arrested form between 
the Michaelis complex and the transition state. Combination of these data with previously reported 
spectroscopic and X-ray crystallographic data have allowed a detailed mechanism of action to be proposed for 
the metal-mediated peptide hydrolysis reaction catalyzed by AAP. 
Materials and Methods 
Purification of AAP.  
All chemicals used in this study were purchased commercially and of the highest quality available. The AAP was 
purified from a stock culture kindly provided by Professor Céline Schalk. Cultures were grown according to the 
previously published procedure (20) with minor modifications to the growth media (21). Purified enzyme was 
stored at −80 °C until needed. 
Spectrophotometric Assay of AAP.  
AAP activity was measured by the method of Prescott and Wilkes (22) as modified by Baker et al. (23). In this 
assay, the hydrolysis of 0.5 mM l-leucine-p-nitroanilide (10 mM Tricine, pH 8.0, containing 0.1 mM ZnSO4) was 
measured spectrophotometrically at 25 °C by monitoring the formation of p-nitroaniline. The extent of 
hydrolysis was calculated by monitoring the increase in absorbance at 405 nm (Δε405 value of p-nitroaniline of 
10 800 M-1 cm-1) (23). One unit was defined as the amount of enzyme that releases 1 μmol of p-nitroaniline at 25 
°C in 60 s. The specific activity of purified AAP was typically found to be 120 units/mg of enzyme. This value is 
identical to that reported by Prescott and Wilkes (20). All spectrophotometric assays were performed on a 
Shimadzu UV-3101PC spectrophotometer equipped with a constant temperature cell holder. Enzyme 
concentrations were determined from the absorbance at 278 nm with the value ε278 = 41 800 M-1 cm-1 (24). 
Crystallization, Data Collection, and Processing.  
AAP was cocrystallized with BuBA using the crystallization conditions reported for the native enzyme (25), 
following preincubation with a 4-fold molar excess of BuBA. The purified AAP (10 mg·mL-1) in 10 mM Tris at pH 
8.0, 10 mM KSCN, 0.4 M NaCl, and 4-fold molar excess of BuBA was crystallized by vapor diffusion using 100 mM 
Tris at pH 8.0, 100 mM KSCN, and 4.5 M NaCl as the precipitating solution. Crystals with dimensions 0.7 × 0.4 × 
0.4 mm3 were obtained in 2 days and were shown to be isomorphous with the native crystals. 
Diffraction data were collected at 4 °C on an R-axis IIC Image plate area detector system mounted on a Rigaku 
RU-200B rotating anode generator, operating at 45 kV and 130 mA. A 0.5 mm collimator was used, and the 
crystal to detector distance was 100 mm. One crystal was used with one orientation, but the oscillation step size 
was changed from 1 to 0.5 deg before completing the data collection. The data were processed using XDS97 
(26). The data processing and refinement statistics are outlined in Table 1. The overall completeness of 84% was 
lowered by the completeness of the outermost shell. In the outermost shell (2.1−1.9 Å), the completeness was 
only 46.7%, whereas the completeness in the next resolution shell (2.3−2.1 Å) was 93%. The Rmerge in this 
outermost shell was 37.8%, resulting in an overall Rmerge (on I) of 13.4%, including these data. Ultimately, the 
decision to keep all of the data to 1.9 Å was based on the quality of the electron density maps where these data 
were included. 
Table 1:  Data Collection and Refinement Statistics 
Crystal Data 
space group P6122 






























a Rmerge = ∑|Iobs − Iavg|/∑Iavg.b R-factor = ∑|Fobs − Fcalc|/∑|Fobs|.c As determined by the program PROCHECK. 
Structure Solution and Refinement. Since the crystal of the BuBA-inhibited enzyme was isomorphous with that of 
the native enzyme, the phases from the published native structure (1AMP, ref 15) were used as the starting 
model (15). In this process, the zinc atoms and water molecules were omitted from the original coordinate file. 
All refinement procedures were carried out using the software package X-PLOR (27), and the initial model was 
subjected to a rigid body refinement using reflections in the 20−4.0 Å resolution range. Subsequent rounds of 
positional refinement were carried out using higher resolution data incrementally to 1.9 Å resolution. The R-
factor and R-free (28) at this point were 0.27 and 0.31, respectively. Difference electron density maps with 
coefficients 2Fobs − Fcalc and Fobs − Fcalc (29, 30) were then calculated; these showed clear electron density in the 
active site for the missing zinc atoms as well as bound inhibitor and a water molecule in close proximity to the 
bound inhibitor. The two zinc ions and several water molecules were added, and the model was subjected to 
further rounds of positional refinement. To avoid any bias toward the form of the inhibitor during refinement of 
the structure, the inhibitor was not yet built into the electron density. Only after several more rounds of 
refinement and the addition of more water molecules were the coordinates for BuBA built into the electron 
density. A model for BuBA was built using QUANTA (Molecular Simulations, Inc.) in an almost pyramidal 
arrangement. This model of BuBA was fitted into the observed electron density in a form having only two 
oxygen ligands. This electron density showed no sign of a third oxygen atom attached to the boron atom. 
Because the density at the boron atom was clearly not planar, the parameter files for the inhibitor were edited 
such that the constraints placed on all angles within the inhibitor were relaxed during refinement. Without 
relaxing these constraints, the inhibitor was not able to fit the electron density accurately. 
An attempt was made to build into the electron density a form of the inhibitor having three oxygen atoms 
around the boron atom, despite the lack of visible electron density for the third oxygen. This was impossible, 
however, because of the extremely close proximity of water-53. The distance between this water molecule and 
the putative third oxygen atom was only 1.1 Å. This information combined with the lack of electron density for a 
third oxygen caused us to build the inhibitor with only two oxygen atoms. To be sure that the distance between 
the boron atom and water-53 was not due to deficiencies in the parameters used, the structure was also 
subjected to a refinement protocol in which all van der Waals and electrostatic interaction terms between 
water-53 and BuBA were turned off. The distance between water-53 and the boron atom remained unchanged 
after such refinement. 
The electron density for the inhibitor did not extend to the last carbon of BuBA, and this carbon was, therefore, 
not built into the structure. Further rounds of positional refinement as well as overall and individual B-factor 
refinement resulted in a final structure with an R-factor of 0.19 and an R-free of 0.23. At this resolution the 
anticipated error in the coordinate positions is 0.1−0.2 Å. In addition to the 291 amino acid residues, the final 
model contains 2 zinc ions, 134 water molecules, and 6 atoms of the inhibitor molecule. The terminal carbon of 
BuBA was omitted due to lack of electron density. Simulated annealing omit maps, in which the active site 
region was omitted, were calculated and confirmed the presence and the geometry of the bound inhibitor and 
water-53. 
Results and Discussion 
Spectroscopic and crystallographic studies on aminopeptidases, to date, have focused on the native enzymes 
and analogues of the tetrahedral transition state of peptide hydrolysis. These include studies on transition state 
analogue complexes of both bovine lens leucine aminopeptidase (blLAP) and AAP, which have been interpreted 
in terms of various catalytic steps (16−18, 31, 32). For AAP, kinetic, optical, and EPR data on the binding of l-
leucinephosphonic acid (LPA) to the dicobalt(II)-substituted ([CoCo(AAP)]) enzyme and the heterobimetallic 
([CoZn(AAP)] and [ZnCo(AAP)]) enzymes suggested that a single oxygen atom bridge is not present in this 
complex (19). Since LPA was shown to interact with both metal centers, LPA was proposed to bind to the 
binuclear cluster of AAP as an η-1,2-μ-phosphonate with one of the ligands at the second divalent metal ion 
provided by the N-terminal amine. The proposed structure for LPA binding is consistent with preliminary X-ray 
crystallographic data for [ZnZn(AAP)] bound by LPA (De Paola, unpublished results). The X-ray crystal structure 
of the transition state analogue inhibitor d-iodophenylalanine hydroxamate bound to AAP also indicated both 
metal ions are involved in binding the inhibitor (16). Similarly, X-ray crystal structures of blLAP with the 
transition state analogue inhibitors LPA and l-leucine bound to the binuclear Zn(II) cluster show that both 
inhibitors provide a single oxygen atom bridge between the two Zn(II) ions (17, 18). These data suggest that in 
the transition state of peptide hydrolysis, both metal ions are involved in coordinating the tetrahedral 
intermediate. 
A mechanism was proposed for blLAP in which both active site metal ions function as Lewis acids (18). In this 
mechanism, a bridging hydroxide ion acts as the nucleophile by attacking the scissile carbonyl carbon of the 
peptide substrate. However, for AAP, a mechanism like that of thermolysin or carboxypeptidase A was proposed 
on the basis of an active-site carboxylate that forms a hydrogen bond to the bridging oxygen atom of the 
inhibitor d-iodophenylalanine hydroxamate (16, 31, 32). These structures of transition state analogue complexes 
have been interpreted as representing one stage of the reaction mechanism. Consequently, a number of aspects 
of the hydrolytic chemistry catalyzed by the binuclear metal clusters of aminopeptidases have gone unexplored. 
To examine the interactions of an AAP complex representing an earlier stage of the reaction, we have 
crystallized AAP in the presence of the putative substrate analogue inhibitor 1-butaneboronic acid (BuBA). The 
structure of the AAP−BuBA complex has been determined to 1.9 Å resolution (Figure 2). 
 
Figure 2 Ribbon diagram of the X-ray crystal structure of AAP complexed with 1-butaneboronic acid (BuBA) 
(top). The two zinc(II) ions are depicted as gray spheres. The bridging Asp117 is also shown. Stereoimage of the 
AAP−BuBA complex active site (bottom). BuBA is bound asymmetrically with respect to the zinc ions. In this 
view, water-53 is located behind BuBA. 
 
Boronic acids have been reported to be competitive, slow-binding inhibitors of aminopeptidases. For instance, 
α-aminoboronic acids are known to be biphasic slow-binding aminopeptidase inhibitors (33). The boronic acid 
BuBA (Ki = 10 μM at pH 8.0) (34) binding to AAP has been previously studied by probing the [CoCo(AAP)], 
[CoZn(AAP)], and [ZnCo(AAP)] enzyme−complexes by EPR spectroscopy (35, 36). The addition of BuBA to 
[CoZn(AAP)] resulted in a distinct change in the EPR spectrum; however, addition of BuBA to [ZnCo(AAP)] left the 
EPR spectrum completely unperturbed. These data are similar to those obtained from electronic absorption 
spectroscopy (37) and indicate that BuBA binds only to the first metal binding site of AAP and does not interact 
with the second site. Furthermore, the addition of 1 equiv of BuBA to [CoCo(AAP)] resulted in the immediate 
loss of an integer spin (S = 3) EPR signal observed in the parallel mode, suggesting that upon BuBA binding the μ-
aquo bridge between the Co(II) ions is lost and becomes terminal on the first metal-binding site (31, 38). The 
newly generated terminal water/(OH-) then becomes a candidate for the nucleophile in the enzymatic reaction. 
Comparison of these data with the spectroscopic and X-ray crystallographic results for transition-state-analogue 
inhibitors suggests that BuBA mimics the substrate binding step rather than the transition state (36). 
BuBA binding to AAP does not induce major conformational changes in the protein, and the structures of the 
native AAP and AAP−BuBA complex agree well with an rms deviation of 0.17 Å for the 291 structurally 
equivalent Cα atoms (Figure 2). The two Zn(II) atoms are 3.3 Å apart in the BuBA complex compared to 3.5 Å in 
the native structure. This difference is not significant at this resolution. The amino acid residues ligated to the 
dizinc(II) cluster are identical to those of the native structure with only minor perturbations to the bond lengths 
(Figure 3, Table 2). The BuBA oxygen atoms are 2.5 and 2.7 Å from Zn1 and 3.0 and 4.4 Å from Zn2 suggesting 
that BuBA binds only to Zn1 and not to Zn2, consistent with previous EPR studies (35). 
 
Figure 3 Schematic of BuBA bound to AAP with distances (Å) shown for all ligands to the zinc ions and for water-
53. 
 
Table 2:  Selected Bond Lengths (Å) for the Zinc-ligand Distances in the AAP−BuBA Complex 
  zinc−ligand distance (Å)  
zinc−ligand native BuBA complex 
Zn1−Zn2 3.5 3.3 
Zn1−Asp117 O2 2.1 2.2 
−Glu152 O1 2.0 2.2 
−Glu152 O2 2.4 2.6 
−His256 N2 2.3 2.3 
bridging H2O/OH- 2.3   
−BuBA O1   2.5 
−BuBA O2   2.7 
Zn2−Asp117 O1 2.0 2.1 
−Asp179 O1 2.1 2.2 
−Asp179 O2 2.3 2.5 
−His97 N2 2.3 2.2 
bridging H2O/OH- 2.3   
−BuBA O2   3.0 
−BuBA O1   4.4 
water-53−boron   2.4 
−Zn1   4.3 
−Zn2   4.8 
 
An interesting finding in this study is that the boron atom of BuBA is clearly not trigonal planar (sp2) but is 
trigonal pyramidal (sp3) (Figure 4). In the absence of enzyme, BuBA was reported to be >99% in the boronic acid 
form (sp2 hybridized) at pH 8.0, with a reported pKa of 10.62 (34). Therefore, the loss of planarity about the 
boron atom must be the result of binding to the binuclear active site of AAP. In addition, there is no electron 
density near the two Zn(II) ions that would suggest a bridging water between them in the AAP−BuBA complex. A 
new water molecule (water-53) that was not present in the native structure resides 2.4 Å from the boron atom 
of BuBA. Although rather far from both Zn(II) ions (4.3 Å from Zn1 and 4.8 Å from Zn2), water-53 may in fact 
represent the nucleophile in the catalytic reaction since it resides on the correct side of the boron atom to have 
been delivered by Zn1. Moreover, it is well positioned for an in-line attack on the carbonyl carbon atom of the 
peptide substrate if the N-terminal amino acid were bound analogously to BuBA with the carbonyl carbon in the 
position of the boron atom. On the basis of these data, it is reasonable to propose that the sp2 hybridized form 
of BuBA binds to the dinuclear active site of AAP via the coordination of O1 to Zn1. This initial binding step 
would then be followed by attack of the active site Zn1-bound water/(OH-) to the electron deficient pz orbital of 
the boron atom, making it sp3. These data are consistent with previous kinetic studies on BuBA binding to AAP, 
which indicated that BuBA binds in a two-step process (34, 37) analogous to the binding of boronic acids to 
serine proteases (38). Therefore, the AAP−BuBA complex could represent the proteolytic reaction in an arrested 
form between the Michaelis complex and the transition state. This structure of a reaction intermediate is the 
only one of its kind for a binuclear hydrolytic system. 
 
Figure 4 Final difference electron density map with coefficients 2Fobs − Fcalc contoured at 1.2σ showing the two 
zinc ions, BuBA, and water-53, proposed to be the active site nucleophile. For clarity, the electron density of the 
protein ligands to the metal ions has been omitted from this figure. 
 
The boron atom of BuBA bound to AAP appears to be in a tetrahedral form with a water molecule or a hydroxyl 
ion nearby. Thus, the question arises:  why is the AAP−BuBA complex not a reasonable mimic for a post-
transition state structure? This question is based on the expectation that hydrolysis of the peptide bond occurs 
by the formation of a tetrahedral intermediate and the additional expectation that the transition state leading 
to this intermediate is similar in structure. Since one expects the distances between boron and oxygen to be 
almost equal for the ionized boronate and since the distance between water-53 and the boron atom is long (2.4 
Å), this is indicative of an early event surrounding the transition state. The fact that an arrested form of the 
catalytic reaction is observed even though this is not a thermodynamically stable step along the catalytic 
pathway is likely due entirely to the inhibitor, BuBA. First, when the boron atom of BuBA is sp2hybridized with a 
trigonal planar geometry, the pz orbital is empty and the boron is deficient making the boron an excellent Lewis 
acid. Moreover, upon binding of the O1 oxygen atom of BuBA to Zn1, the boron atom of BuBA will become more 
electron deficient. This results in the boron atom of BuBA becoming even more susceptible to nucleophilic 
attack by an active-site water/(OH-) molecule. Second, the n-butyl tail is a poor leaving group, and the 
boron−carbon bond cannot be broken. Consequently, the hydrophobic interactions between the n-butyl group 
and the hydrophobic pocket may be sufficiently inflexible so that the oxygen atom of BuBA, that is 3.0 Å from 
Zn2, cannot move enough to bind to Zn2, forming a transition state type structure. 
The binuclear center in the native enzyme is structurally symmetric (15), and AAP is ca. 80% active with only a 
single metal ion bound (35, 39). These observations pose an important mechanistic question:  what is the driving 
force to break the Zn2−OH(H) bond, leaving the putative nucleophile (OH-) and the substrate on the same zinc 
(Zn1) ion? Several active-site amino acid residues that do not act as Zn(II) ligands form hydrogen bonds within 
the active site. One of these, Glu151, contains an oxygen atom that in the AAP−BuBA complex is 3.0 Å from the 
coordinated Nε-nitrogen atom of His97, which is a ligand to Zn2. This distance is significantly shorter than the 
3.4 Å distance found in the native structure and allows for a hydrogen bond between Glu151 and His97 that may 
not have existed in the native structure, or only existed weakly or transiently. These data suggest that Glu151 
may contribute to the regulation of the Lewis acidity of Zn2. A second hydrogen bonding interaction is observed 
between Asp99 and His97 forming an Asp-His-Zn triad. An oxygen atom of Asp99 is 2.7 Å from the Nδ-nitrogen 
of His97, suggesting a strong hydrogen bonding interaction. Strong hydrogen bonds between active site Asp 
residues and histidine ligands in zinc metalloproteins have been shown previously to provide a histidinate-like 
ligand (40), thus decreasing the Lewis acidity of Zn(II) ions. For Zn2, coordination of Asp179 and Asp117 results 
in significant negative charge around the metal ion. Therefore, the hydrogen bond between His97 and Asp99 
provides a histidinate-like ligand that allows Zn2 to retain charge neutrality. If this hydrogen bond is sufficiently 
strong, which appears to be the case in the AAP−BuBA structure, this interaction may also decrease the Lewis 
acidity of Zn2 sufficiently to assist in the loss of the bridging water/(OH-). The combination of these hydrogen 
bonding interactions may, therefore, act to destroy the local symmetry of the binuclear cluster as well as 
decrease the Lewis acidity of the Zn2 ion, allowing both the substrate and nucleophile to reside on the Zn1 site. 
On the basis of previously reported kinetic, thermodynamic, spectroscopic, and X-ray crystallographic data a 
detailed mechanism of action for AAP has recently been proposed (19, 35, 36). In this mechanism, the bridging 
water/(OH-) becomes terminal upon substrate binding and remains associated with the Zn1. An active-site 
carboxylate group, Glu151, has been implicated in the catalytic process from X-ray crystallographic data since 
Glu151 forms a hydrogen bond with the bridging water/(OH-) molecule in the resting enzyme (15). The role of 
Glu151 could be to assist in the deprotonation of the terminal water molecule to the nucleophilic hydroxo 
moiety, a role similar to that proposed for Glu270 in carboxypeptidase A (41). Our structural data for the 
AAP−BuBA complex are consistent with this mechanism. Recent studies by us on the structures of peptide-
derived inhibitors bound to AAP are also consistent with this picture, and the terminal amino group of these 
peptide analogues is observed to coordinate to Zn2 (19, De Paola, unpublished results). N-Terminal amine 
binding to Zn2 suggests that electron density donation by the second metal ion is important in stabilizing the 
transition state. Similarly, amine binding to the second Mn(II) ion in arginase has been proposed to drive the loss 
of the bridging water/(OH-) to form a terminal hydroxide that functions as the nucleophile in that hydrolytic 
reaction (42). On the basis of these data, we propose that N-terminal amine binding, in conjunction with 
hydrogen-bonding interactions between Glu151 and/or Asp99 with His97, could function to displace the 
bridging water/(OH-) thus placing it on Zn1 along with the substrate. At this point, the metal-bound hydroxide 
can attack the activated scissile carbonyl carbon of the peptide substrate, forming a gem-diolate intermediate 
complex that is stabilized by coordination of both oxygen atoms to the dizinc(II) center. Glu151 can then provide 
an additional proton to the penultimate amino nitrogen returning it to its ionized state. Finally, the dizinc(II) 
cluster releases the cleaved products followed by the addition of a water molecule to bridge between the two 
metal ions. This model predicts that both metal ions are required for full enzymatic activity by this mechansim, 
but their individual roles differ markedly. 
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